Blocking only the bad side of IL-6 in inflammation and cancer
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Forschungsgemeinschaft (CRC841, CRC877)
- Deutsche Krebshilfe
- Exzellenzclusters Entzündungsforschung
This publication has 124 references indexed in Scilit:
- Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studiesThe Lancet, 2012
- Therapeutic strategies for the clinical blockade of IL-6/gp130 signalingJournal of Clinical Investigation, 2011
- Species Specificity of ADAM10 and ADAM17 Proteins in Interleukin-6 (IL-6) Trans-signaling and Novel Role of ADAM10 in Inducible IL-6 Receptor SheddingJournal of Biological Chemistry, 2011
- Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in miceJournal of Experimental Medicine, 2010
- IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated CancerCancer Cell, 2009
- Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumoursNature, 2008
- Forced Dimerization of gp130 Leads to Constitutive STAT3 Activation, Cytokine-independent Growth, and Blockade of Differentiation of Embryonic Stem CellsMolecular Biology of the Cell, 2006
- STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit miceGut, 2006
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006
- An Essential Role for Ectodomain Shedding in Mammalian DevelopmentScience, 1998